Skip to Content
Merck
CN
All Photos(3)

Documents

Safety Information

E5389

Sigma-Aldrich

Erythromycin

powder, suitable for cell culture, BioReagent

Synonym(s):

E-Mycin, Erythrocin

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C37H67NO13
CAS Number:
114-07-8
Molecular Weight:
733.93
Beilstein:
75279
EC Number:
204-040-1
MDL number:
MFCD00084654
UNSPSC Code:
12352207
PubChem Substance ID:
24894612
NACRES:
NA.76

product name

Erythromycin, BioReagent, suitable for cell culture

product line

BioReagent

Quality Level

200

form

powder

potency

≥850 μg per mg

technique(s)

cell culture | mammalian: suitable

impurities

≤0.1 EU/mg endotoxin

color

white

mp

133 °C

solubility

2 M HCl: 50 mg/mL (Stock solutions should be stored at 2-8 °C. Stable at 37 °C for 3 days.)
ethanol: soluble (Stock solutions should be stored at 2-8 °C. Stable at 37 °C for 3 days.)

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria

Mode of action

protein synthesis | interferes

SMILES string

CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

InChI

1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1

InChI key

ULGZDMOVFRHVEP-RWJQBGPGSA-N

Gene Information

human ... ABCB1(5243) , CYP3A4(1576) , MLNR(2862)
mouse ... Abcb1a(18671) , Abcb1b(18669)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Chemical structure: macrolide
Erythromycin is an antibiotic produced by growth of certain strains of Streptomyces erythreus. This product is composed largely of erythromycin A with small amounts of erythromycins B and C and is recommended for concentration at 100 mg/L. Concentrations between 50 and 200 mg/L have also proven effective in controlling bacterial growth. Erythromycin has been used as a motilin receptor agonist, to block respiratory glycoconjugate secretion in human airways in vitro, and for selecting plasmid-cured and recombinant lactococcus lactis MG1363 strains.

Application

Erythromycin has been used:
  • as a supplement for nutrient broth medium for culturing green fluorescent protein (GFP)- expressing E. coli
  • as a model drug to determine small intestinal (SMI) microtissue viability using the MTT assay{254
  • as an antibiotic to study the treatment strategies of chronic infections

Biochem/physiol Actions

Mode of Action: Erythromycin acts by inhibiting elongation at the transpeptidation step, specifically aminoacyl translocation from the A-site to P-site by binding to the 50s subunit of the bacterial 70s rRNA complex.

Antimicrobial Spectrum: This product acts against both gram-negative and gram-positive bacteria.

Caution

This product is stable in solution at 37°C for 3 days. Stock solutions should be stored at 2-8°C.

Preparation Note

This product is soluble in water at 2 mg/mL, with a 0.067% solution in water yielding a pH of 8.0-10.5. It is also soluble in ethanol at 50 mg/mL, yielding a clear, colorless to faint yellow solution. It is freely soluble in alcohol, acetone, chloroform, acetonitrile and ethyl acetate but forms salts with acids. All solutions should be protected from light.

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

涉药品监管产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Drug-driven phenotypic convergence supports rational treatment strategies of chronic infections
Imamovic L, et al.
Cell, 172(1-2), 121-134 (2018)
Acoustofluidic bacteria separation
Li S, et al.
Journal of Micromechanics and Microengineering, 27(1), 015031-015031 (2016)
Maopeng Wang et al.
International journal of biological macromolecules, 160, 736-740 (2020-06-03)
Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic in the past four months and causes respiratory disease in humans of almost all ages. Although several drugs have been
Geert Huys et al.
Antimicrobial agents and chemotherapy, 54(6), 2567-2574 (2010-04-14)
In a small-scale harmonization study involving nine laboratories in eight European countries, the intra- and interlaboratory performances of two commercially available systems, i.e., the VetMIC microplate system and Etest, for antimicrobial susceptibility testing of nonenterococcal lactic acid bacteria (NELAB) and
Won Jong Kim et al.
Cell host & microbe, 26(2), 228-239 (2019-08-06)
The mucosa is colonized with commensal Neisseria. Some of these niches are sites of infection for the STD pathogen Neisseria gonorrhoeae (Ngo). Given the antagonistic behavior of commensal bacteria toward their pathogenic relatives, we hypothesized that commensal Neisseria may negatively
View All Related Papers

Articles

Inhibition of Protein Synthesis by Antibiotics

Antibiotics targeting bacterial ribosomes disrupt protein synthesis, a key process in bacterial growth inhibition.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service